• Avadel Pharmaceuticals Issues 2018 Corporate Outlook biospace
    January 02, 2018
    Avadel Pharma (NASDAQ:AVDL), “Avadel” or “the Company,” today announced its 2018 corporate objectives and financial expectations, including the commercial launch of Noctiva™ and the anticipated filing of a New Drug Application (NDA) for both FT218
PharmaSources Customer Service